ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX) | |||||||
SCHEDULE OF INVESTMENTS (Unaudited) | |||||||
December 31, 2023 | |||||||
Shares | Fair Value | ||||||
COMMON STOCKS — 87.7% | |||||||
BIOTECH & PHARMA - 77.4% | |||||||
267,500 | Abivax S.A. - ADR(a) | $ 2,862,250 | |||||
26,000 | ACADIA Pharmaceuticals, Inc.(a) | 814,060 | |||||
140,000 | Amicus Therapeutics, Inc.(a) | 1,986,600 | |||||
151,000 | Amylyx Pharmaceuticals, Inc.(a) | 2,222,720 | |||||
7,750 | Argenx S.E. - ADR(a) | 2,948,333 | |||||
50,000 | Aurinia Pharmaceuticals, Inc.(a) | 449,500 | |||||
7,500 | BeiGene Ltd. - ADR(a) | 1,352,700 | |||||
90,000 | Bicycle Therapeutics plc - ADR(a) | 1,627,200 | |||||
675,000 | BioCryst Pharmaceuticals, Inc.(a) | 4,043,250 | |||||
14,000 | BioMarin Pharmaceutical, Inc.(a) | 1,349,880 | |||||
25,000 | Cerevel Therapeutics Holdings, Inc.(a) | 1,060,000 | |||||
1,000,000 | Coherus Biosciences, Inc.(a) | 3,330,000 | |||||
10,000 | Cymabay Therapeutics, Inc.(a) | 236,200 | |||||
112,500 | Deciphera Pharmaceuticals, Inc.(a) | 1,814,625 | |||||
100,000 | Dynavax Technologies Corporation(a) | 1,398,000 | |||||
105,000 | Galapagos N.V. - ADR(a) | 4,268,250 | |||||
8,500 | Gilead Sciences, Inc. | 688,585 | |||||
35,000 | GSK plc - ADR | 1,297,100 | |||||
122,000 | Harmony Biosciences Holdings, Inc.(a) | 3,940,600 | |||||
127,500 | ImmunoGen, Inc.(a) | 3,780,375 | |||||
38,000 | Immunovant, Inc.(a) | 1,600,940 | |||||
20,000 | Intra-Cellular Therapies, Inc.(a) | 1,432,400 | |||||
245,000 | Ironwood Pharmaceuticals, Inc.(a) | 2,802,800 | |||||
10,500 | Jazz Pharmaceuticals plc(a) | 1,291,500 | |||||
137,000 | KalVista Pharmaceuticals, Inc.(a) | 1,678,250 | |||||
3,500 | Karuna Therapeutics, Inc.(a) | 1,107,785 | |||||
1,125,000 | Karyopharm Therapeutics, Inc.(a) | 973,125 | |||||
50,000 | Mirum Pharmaceuticals, Inc.(a) | 1,476,000 | |||||
450,000 | Nuvation Bio, Inc.(a) | 679,500 | |||||
117,500 | Pacira BioSciences, Inc.(a) | 3,964,450 | |||||
80,000 | Pfizer, Inc. | 2,303,200 | |||||
30,000 | Protagonist Therapeutics, Inc.(a) | 687,900 | |||||
220,000 | Revance Therapeutics, Inc.(a) | 1,933,800 | |||||
16,000 | Roche Holding A.G. - ADR | 579,680 |
ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX) | |||||||
SCHEDULE OF INVESTMENTS (Unaudited) (Continued) | |||||||
December 31, 2023 | |||||||
Shares | Fair Value | ||||||
COMMON STOCKS — 87.7% (Continued) | |||||||
BIOTECH & PHARMA - 77.4% (Continued) | |||||||
55,000 | Roivant Sciences Ltd.(a) | $ 617,650 | |||||
40,000 | Royalty Pharma plc, Class A | 1,123,600 | |||||
30,000 | Structure Therapeutics, Inc. - ADR(a) | 1,222,800 | |||||
421,025 | uniQure N.V.(a) | 2,850,339 | |||||
18,000 | United Therapeutics Corporation(a) | 3,958,020 | |||||
155,000 | UroGen Pharma Ltd.(a) | 2,325,000 | |||||
34,298 | Valneva S.E. - ADR(a) | 352,926 | |||||
10,000 | Ventyx Biosciences, Inc.(a) | 24,700 | |||||
150,000 | Verastem, Inc.(a) | 1,221,000 | |||||
56,000 | Verona Pharma plc - ADR(a) | 1,113,280 | |||||
35,000 | Viatris, Inc. | 379,050 | |||||
668,151 | VYNE Therapeutics, Inc.(a) | 1,556,792 | |||||
80,726,715 | |||||||
HEALTH CARE FACILITIES & SERVICES - 1.7% | |||||||
310,000 | DocGo, Inc.(a) | 1,732,900 | |||||
MEDICAL EQUIPMENT & DEVICES - 5.6% | |||||||
200,000 | Embecta Corporation | 3,786,000 | |||||
5,000 | Inari Medical, Inc.(a) | 324,600 | |||||
20,500 | Medtronic PLC | 1,688,790 | |||||
5,799,390 | |||||||
RETAIL - CONSUMER STAPLES - 3.0% | |||||||
120,000 | Walgreens Boots Alliance, Inc. | 3,133,200 | |||||
TOTAL COMMON STOCKS (Cost $95,132,528) | 91,392,205 | ||||||
Expiration Date | Exercise Price | ||||||
RIGHT — 0.0%(b) | |||||||
BIOTECH & PHARMA - 0.0% (b) | |||||||
300,000 | Amryt Pharma, PLC. – CVR (a) (d) (e) | 12/31/2024 | $ 0.50 | – | |||
300,000 | Amryt Pharma, PLC. - CVR (a) (d) (e) | 12/31/2024 | $ 0.50 | – | |||
TOTAL RIGHT (Cost $0) | – |
ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX) | |||||||
SCHEDULE OF INVESTMENTS (Unaudited) (Continued) | |||||||
December 31, 2023 | |||||||
Shares | Fair Value | ||||||
SHORT-TERM INVESTMENTS — 11.3% | |||||||
MONEY MARKET FUNDS - 11.3% | |||||||
1 | Fidelity Money Market Government Portfolio, Class I, 5.24%(c) | $ 1 | |||||
11,786,585 | First American Treasury Obligations Fund, Class X, 5.28%(c) | 11,786,585 | |||||
TOTAL MONEY MARKET FUNDS (Cost $11,786,586) | 11,786,586 | ||||||
TOTAL INVESTMENTS - 99.0% (Cost $106,919,114) | $ 103,178,791 | ||||||
OTHER ASSETS IN EXCESS OF LIABILITIES - 1.0% | 1,052,395 | ||||||
NET ASSETS - 100.0% | $ 104,231,186 | ||||||
ADR | - American Depositary Receipt |
CVR | - Contingent Value Right |
LTD | - Limited Company |
NV | - Naamioze Vennootschap |
PLC | - Public Limited Company |
S/A | - Société Anonyme |
(a) | Non-income producing security. |
(b) | Percentage rounds to less than 0.1%. |
(c) | Rate disclosed is the seven day effective yield as of December 31, 2023. |
(d) | Illiquid security. The total fair value of these securities as of December 31, 2023 was $0, representing 0.0% of net assets. |
(e) | Fair Valued by the Board of Trustees in good faith using significant unobservable inputs. |